Want to see AIDX full AI Analyst Report?
AIDX Stock Chart & Stats
$1.78
--
Market closed
$1.78
--
Day’s Range― - ―
52-Week Range$0.51 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$6.34M
Enterprise Value$37.71K
Total Cash (Recent Filing)$4.22M
Total Debt (Recent Filing)$925.49K
Price to Earnings (P/E)―
Beta2.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,251,198
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.20
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$5.00Price Target Upside180.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA clear revenue rebound in 2025 signals restored demand and the ability to re-fill lab capacity. If sustained, higher top-line supports fixed-cost absorption, improves operating leverage, and provides a tangible foundation to rebuild margins and reduce near-term reliance on external financing.
Improved Gross MarginAn improvement to ~29.6% gross margin reflects better pricing, mix, or cost control at the service level. Sustained higher gross margin materially narrows the gap to profitability by protecting incremental revenue and enabling investments in scale without proportionate margin erosion.
Focused Diagnostics BusinessA focused clinical-lab model concentrating on blood-based diagnostic assays creates structural demand from providers and patients. Specialized testing and reporting can build durable customer relationships, recurring volume patterns, and differentiation versus commodity lab services if quality and turnaround are consistent.
Bears Say
Extremely High LeverageVery high debt and negative equity materially weaken financial resilience. Leverage constrains strategic choices, raises refinancing and covenant risks, and can force priority to creditor servicing over operational investment, impairing long-term growth and survival prospects absent recapitalization.
Large Cash BurnMassive negative operating and free cash flow denotes structural funding dependence. Ongoing cash burn increases probability of dilution or distressed financings, limits capacity to invest in R&D or capacity, and reduces runway to execute any multi-quarter recovery plans without external capital.
Sustained Negative ProfitabilityMulti-year negative operating and net margins indicate the cost base and business model are not yet profitable at current scale. Persistent losses suggest structural issues—pricing, utilization, or fixed costs—that must be addressed to achieve durable profitability even if revenue growth continues.
20/20 Biolabs, Inc. News
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.51 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $6.34M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Undervalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 12,251,198 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
AIDX Stock 12 Month Forecast
Average Price Target
$5.00
▲(180.90% Upside)
Biomerica
―
Co-Diagnostics
―
Lucid Diagnostics
―
Bluejay Diagnostics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
0.43% Insiders
<0.01% Other Institutional Investors
99.37% Public Companies and
Individual Investors